Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer

Equality Impact Assessment (Guidance development) (PDF 146 KB)

Final draft guidance

Committee papers (PDF 6.97 MB)

Final appraisal document (PDF 204 KB)

Equality impact assessment (Scoping) (PDF 125 KB)

Final scope (PDF 171 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 249 KB)

Final stakeholder list (PDF 183 KB)

Draft scope post referral (PDF 180 KB)

Draft matrix post referral (PDF 183 KB)

Draft scope post referral (PDF 208 KB)

Draft matrix post referral (PDF 183 KB)